Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Basic studies on a new material for inducing antitumor immune cells.

Z Yamazaki1, M Hiraishi, F Kanai

  • 1University of Tokyo, Japan.

ASAIO Transactions
|July 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adenovirus-mediated drug-sensitivity gene therapy for hepatocellular carcinoma.

Methods in molecular medicine·2011
Same author

Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test.

Journal of viral hepatitis·2010
Same author

Influence of anti-HBc seropositivity on the risk of hepatocellular carcinoma in HCV-infected patients after adjusting for confounding factors.

Journal of viral hepatitis·2009
Same author

Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH.

Gut·2009
Same author

Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients.

Oncogene·2005
Same author

The hepatitis B virus X protein enhances AP-1 activation through interaction with Jab1.

Oncogene·2005

A new material, CMC-1, effectively induces potent antitumor killer cells from human lymphocytes with short-term stimulation. This offers a potential solution to the challenges associated with current lymphokine-activated killer (LAK) cell therapy for cancer.

Area of Science:

  • Immunology
  • Biotechnology
  • Oncology

Background:

  • Adoptive immunotherapy using lymphokine-activated killer (LAK) cells is a promising cancer treatment.
  • Current LAK cell therapy faces challenges in handling, sterilization, and time efficiency.
  • Novel materials are needed to improve the induction of antitumor immune cells.

Purpose of the Study:

  • To investigate new materials for inducing antitumor immune cells.
  • To evaluate the efficacy of pokeweed mitogen (PWM) and PWM-conjugated materials (CMC-1) in stimulating killer cells.
  • To assess the potential of CMC-1 as an alternative to current LAK cell therapy.

Main Methods:

  • Short-term stimulation of human peripheral blood lymphocytes (PBL) with PWM and CMC-1.
  • In vitro assessment of killer cell activity against various human tumor cell lines.

Related Experiment Videos

  • In vivo evaluation of CMC-1's tumoricidal effect in tumor-bearing nude mice.

    • Main Results:

    • CMC-1 induced strong killer cells through short-term stimulation of human PBL.
    • The induced killer cells exhibited a broad killing spectrum against multiple human tumor cell lines in vitro.
    • Human PBL stimulated with CMC-1 demonstrated a tumoricidal effect against tumors in vivo.

    Conclusions:

    • CMC-1 effectively induces potent antitumor killer cells with short-term stimulation.
    • CMC-1 may overcome the limitations of current LAK cell therapy.
    • CMC-1 presents a potentially easily applicable extracorporeal immunotherapy for cancer treatment.